Asahi Kasei Kuraray Medical

The Therapeutic Apheresis Division has been introducing innovative therapies for intractable diseases by extending the frontiers of medical devices and systems for extracorporeal treatment, such as plasmapheresis, leukocytapheresis (LCAP), and continuous renal replacement therapy (CRRT).
We have been making our current products better and will develop new products and systems to improve patients’ quality of life (QOL).

Plasmapheresis is a procedure for separating plasma from blood, allowing the removal of pathogenic substances from plasma directly or by indirect treatment.
...more>>

Leukocytapheresis (LCAP) is an extracorporeal blood purification therapy in which leukocytes (granulocytes, monocytes, and lymphocytes) causing inflammation and/or immune deficiency are removed. ...more>>

In conventional hemodialysis, 2-day kidney function is processed in less than 4 hours. In severe cases, however, patients cannot tolerate conventional dialysis because…
...more>>

Trademark
Plasmaflo, Cascadeflo, Rheofilter, Plasorba, Immusorba, Cellsorba, CUREFLO, and Plasauto are trademarks of Asahi Kasei Kuraray Medical Co., Ltd.